There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pacira Pharmaceuticals (NASDAQ:PCRX) and Mirati Therapeutics (NASDAQ:MRTX) with bullish sentiments.
Pacira Pharmaceuticals (PCRX)
In a report released yesterday, Douglas Tsao from Barclays maintained a Buy rating on Pacira Pharmaceuticals, with a price target of $50. The company’s shares closed yesterday at $43.
According to TipRanks.com, Tsao is a 2-star analyst with an average return of 1.3% and a 50.0% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Protagonist Therapeutics, and Perrigo Company plc.
Currently, the analyst consensus on Pacira Pharmaceuticals is a Moderate Buy with an average price target of $49.88, a 16.0% upside from current levels. In a report issued on July 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $48 price target.
.
See today’s analyst top recommended stocks >>
Mirati Therapeutics (MRTX)
In a report released yesterday, Gena Wang from Barclays maintained a Buy rating on Mirati Therapeutics, with a price target of $71. The company’s shares closed yesterday at $61.05, close to its 52-week high of $65.35.
According to TipRanks.com, Wang is a 5-star analyst with an average return of 26.5% and a 54.2% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Sarepta Therapeutics, and Spark Therapeutics.
Currently, the analyst consensus on Mirati Therapeutics is a Strong Buy with an average price target of $62, which is a 1.6% upside from current levels. In a report issued on July 20, H.C. Wainwright also maintained a Buy rating on the stock with a $63 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
